Journal of Diagnostics Concepts & Practice >

2023 , Vol. 22 >Issue 05: 421 - 428

DOI: https://doi.org/10.16150/j.1671-2870.2023.05.002

Academic trend at home and abroad

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML

Expand
  • 1. Department of Laboratory Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Yiwu 322000, China
    2. Yunkang Hematologic Diseases Integrated Diagnosis Center, Guangdong Guangzhou 510700, China

Received date: 2023-03-07

  Online published: 2024-03-15

Fold

Abstract

In 2022, the World Health Organization (WHO) proposed the 5th edition of the WHO Classification of Haematolymphoid Tumours (referred to as the 5th ed. WHO classification) based on the accumulated research results and clinical application progress in related fields after the revised 4th Edition of the WHO classification. Myelodysplastic neoplasms/syndrome (MDS) and acute myeloid leukemia (AML) in the 5th ed. edition of the WHO classification. In practice in WHO classification has major changes from the revised 4th, it is of great significance for clinical disease diagnosis and treatment, as well as disease registration and scientific research. This article is interpreted based on the fifth edition of the classification published in the journal Leukemia and online ahead of print version on the official website of the International Agency for Research on Cancer.

Key words： 5th edition of the WHO Classification of Haematolymphoid Tumours; Myelodysplastic neoplasms; Acute myeloid leukemia

Cite this article

YE Xiangjun, LU Xingguo . Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(05) : 421 -428 . DOI: 10.16150/j.1671-2870.2023.05.002

References

[1] KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms[J]. Leukemia, 2022, 36(7):1703-1719.
[2] HUBER S, HAFERLACH T, MüLLER H, et al. MDS subclassification-do we still have to count blasts?[J]. Leukemia, 2023, 37(4):942-945.
[3] SWERDLOW S H, CAMPO E, HARRIS N L, et al. WHO Classification of Tumours of Haematopoietic and LymphoidTissues[M]. 4th ed.Lyon: IARC, 2017.
[4] CREE I A. The WHO Classification of Haematolymphoid Tumours[J]. Leukemia, 2022, 36(7):1701-1702.
[5] MALCOVATI L, STEVENSON K, PAPAEMMANUIL E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS[J]. Blood, 2020, 136(2):157-170.
[6] BERNARD E, NANNYA Y, HASSERJIAN R P, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020, 26(10):1549-1556.
[7] WHO Classification of Tumours Editorial Board. Haematolymphoid tumours[M]// WHO classification of tumours series. 5th ed. Lyon (France): International Agency for Research on Cancer, 2022.
[8] ESTEY E, HASSERJIAN RP, D?HNER H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal[J]. Blood, 2022, 139(3):323-332.
[9] ARBER D A, ORAZI A, HASSERJIAN R P, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data[J]. Blood, 2022, 140(11):1200-1228.
[10] SOUPIR C P, VERGILIO J A, DAL CIN P, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis[J]. Am J Clin Pathol, 2007, 127(4):642-650.
[11] TARLOCK K, LAMBLE A J, WANG Y C, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group[J]. Blood, 2021, 138(13):1137-1147.
[12] GAO Y, JIA M, MAO Y, et al. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia[J]. Am J Clin Pathol, 2022, 157(5):691-700.
[13] DI GIACOMO D, LA STARZA R, GORELLO P, et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia[J]. Blood, 2021, 138(9):773-784.
[14] WICK N, HITTO I, WELDER D, et al. Acute myeloid leukemia with RAM immunophenotype presenting with extensive mesenteric and retroperitoneal lymphadenopathy: A case report and review of the literature[J]. Leuk Res Rep, 2021, 17:100287.
Options
Outlines

/

〈 〉